Gastroenteritis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Gastroenteritis - Pipeline Review, H1 2016', provides an overview of the Gastroenteritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastroenteritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastroenteritis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Gastroenteritis - The report reviews pipeline therapeutics for Gastroenteritis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Gastroenteritis therapeutics and enlists all their major and minor projects - The report assesses Gastroenteritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Gastroenteritis Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Gastroenteritis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Gastroenteritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Gastroenteritis Overview 6 Therapeutics Development 7 Pipeline Products for Gastroenteritis - Overview 7 Pipeline Products for Gastroenteritis - Comparative Analysis 8 Gastroenteritis - Therapeutics under Development by Companies 9 Gastroenteritis - Therapeutics under Investigation by Universities/Institutes 11 Gastroenteritis - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Gastroenteritis - Products under Development by Companies 15 Gastroenteritis - Products under Investigation by Universities/Institutes 16 Gastroenteritis - Companies Involved in Therapeutics Development 17 Nanotherapeutics, Inc. 17 RedHill Biopharma Ltd. 18 Takeda Pharmaceutical Company Limited 19 UMN Pharma Inc. 20 Gastroenteritis - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 23 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 Antibodies for Gastroenteritis - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 norovirus (bivalent) virus like particle vaccine - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 ondansetron hydrochloride CR - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 TAK-214 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 UMN-2002 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 UMN-2003 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Gastroenteritis - Recent Pipeline Updates 37 Gastroenteritis - Product Development Milestones 43 Featured News & Press Releases 43 Mar 01, 2016: RedHill Biopharma Provides Update on RHB-102 43 Oct 14, 2015: RedHill Biopharma Provides Update on BEKINDA Ongoing Phase III Study for Gastroenteritis and Announces Planned Phase II Study for IBS-D 43 Mar 02, 2015: Positive Bioavailability Studies of RedHill's BEKINDA to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics Meeting 45 Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis 45 Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support 46 Sep 03, 2014: RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis 47 Dec 08, 2011: The New England Journal Of Medicine Publishes Study Showing LigoCyte's Norovirus Vaccine Demonstrates Protection Against Illness 48 Oct 25, 2010: LigoCyte Presents Positive Results From Norovirus Vaccine Challenge Study At IDSA Annual Meeting 50 Appendix 52 Methodology 52 Coverage 52 Secondary Research 52 Primary Research 52 Expert Panel Validation 52 Contact Us 52 Disclaimer 53
List of Tables
Number of Products under Development for Gastroenteritis, H1 2016 7 Number of Products under Development for Gastroenteritis - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Late Stage Development, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 13 Comparative Analysis by Early Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Gastroenteritis - Pipeline by Nanotherapeutics, Inc., H1 2016 17 Gastroenteritis - Pipeline by RedHill Biopharma Ltd., H1 2016 18 Gastroenteritis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 19 Gastroenteritis - Pipeline by UMN Pharma Inc., H1 2016 20 Assessment by Monotherapy Products, H1 2016 21 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Gastroenteritis Therapeutics - Recent Pipeline Updates, H1 2016 37
List of Figures
Number of Products under Development for Gastroenteritis, H1 2016 7 Number of Products under Development for Gastroenteritis - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 14 Assessment by Monotherapy Products, H1 2016 21 Number of Products by Routes of Administration, H1 2016 24 Number of Products by Stage and Routes of Administration, H1 2016 24 Number of Products by Molecule Types, H1 2016 26 Number of Products by Stage and Molecule Types, H1 2016 26
Global glycerol market size is likely to exceed USD 3 billion by 2022, as per a new research report by Radiant Insights, Inc. Regulatory push for promoting bio-diesel production is expected to boost glycerol demand over the forecast period, with expeRead More...
Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demandRead More...
Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global demRead More...
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from mainRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.